Press Releases

Summary ToggleShareholder Update Letter – January 2017

January 15, 2017

Happy New Year from ProLung! 2016 has been a spectacular year. To achieve our research goals more rapidly, we assembled the most extensive team of clinical investigators of lung cancer in pulmonology. This speeds the clinical evaluation required for FDA market approval, sets the stage for rapid

Summary ToggleProLung President & CEO Meets with Gregory C. Simon

December 10, 2016

Steven C.  Eror , President and CEO of ProLung, meets with  Gregory C. Simon , White House Cancer Moonshot Task Force, Executive Director in the Office of the Vice President.

Summary ToggleProLung CEO Interviewed by MergerMarket’s U.S. Healthcare Editor

November 02, 2016

ProLungDX seeks funds for cancer test; sees eventual IPO – CEO Proprietary Intelligence ProLungDX , a maker of lung cancer detection devices, is looking to raise USD 5.25m from high net worth investors for US commercial development in advance of an expected initial public offering or trade sale,

Summary ToggleProLungdx Unveils its EPN Scan® at the BIO Investor Forum: Long-Awaited Test for those at Risk of Lung Cancer

October 13, 2016

Salt Lake City, UT, USA, October 13, 2016 –  ProLungdx™ today announced plans to present its leading-edge innovation for patients at risk of lung cancer during the 2016 BIO Investor Forum in San Francisco, California October 18 and 19, 2016. For the first time in an international biotech

Summary ToggleProLungdx Showcases its EPN Scan® for Lung Cancer at the White Hat Investors Conference

September 07, 2016

Salt Lake City, UT, USA, September 7, 2016 –  ProLungdx™ today announced plans to present its ground-breaking innovation for lung cancer patients at the AZBIO’s 2016 White Hat Life Science Investors Conference in Phoenix, Arizona September 21 and 22, 2016.

Summary ToggleUniversity of Liverpool Lung Cancer Research

June 04, 2016

Lung cancer survival rate increases by 73% if caught early. A major lung cancer screening trial, conducted by experts at the University of Liverpool, has found that patients with a high risk of developing lung cancer can be identified with early stage disease and have up to a 73% chance

Summary ToggleProLungdx Board Names Dr. John C. Ruckdeschel as Newest Board Member

May 26, 2016

Salt Lake City, Utah, May 25, 2016 –  The Board of Directors of Fresh Medical Laboratories Inc., doing business as ProLungdx, today announced the appointment of Dr. John C. Ruckdeschel, M.D. to serve as a Director on the Company’s Board of Directors.  Dr.

Summary ToggleProLungdx Announces Todd Morgan as Chairman of the Board

May 19, 2016

Salt Lake City, Utah, May 19, 2016 –  Fresh Medical Laboratories, Inc, doing business as ProLungdx™, announced today that its board has appointed Todd Morgan as Chairman of the Board of Directors.  Mr. Morgan succeeds Clark Campbell, who served as the Chairman from 2012 to 2016.

Summary ToggleProLungdx EPN Scan® Confirms Performance in Early Lung Cancer Risk Assessment

May 18, 2016

ProLungdx EPN Scan® Confirms Performance in Early Lung Cancer Risk Salt Lake City, Utah, USA, May 18, 2016 –  Fresh Medical Laboratories, Inc., doing business as ProLungdx™, today announced the initial results of its ongoing European Lung Cancer Registry.